Similar articles for PMID: 30346335

Year	Number of Results
2004	3
2007	2
2008	3
2009	6
2010	2
2011	4
2012	2
2013	6
2014	12
2015	17
2016	16
2017	9
2018	5
2019	3
2020	2
2021	7
2022	3
2024	0

1

The Role of Atomoxetine for Parkinson Disease-Related Executive Dysfunction: A Systematic Review.

Warner CB, Ottman AA, Brown JN. Warner CB, et al. J Clin Psychopharmacol. 2018 Dec;38(6):627-631. doi: 10.1097/JCP.0000000000000963. J Clin Psychopharmacol. 2018. PMID: 30346335

2

Atomoxetine restores the response inhibition network in Parkinson's disease.

Rae CL, Nombela C, Rodríguez PV, Ye Z, Hughes LE, Jones PS, Ham T, Rittman T, Coyle-Gilchrist I, Regenthal R, Sahakian BJ, Barker RA, Robbins TW, Rowe JB. Rae CL, et al. Brain. 2016 Aug;139(Pt 8):2235-48. doi: 10.1093/brain/aww138. Epub 2016 Jun 24. Brain. 2016. PMID: 27343257 Free PMC article. Clinical Trial.

3

Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study.

Marsh L, Biglan K, Gerstenhaber M, Williams JR. Marsh L, et al. Mov Disord. 2009 Jan 30;24(2):277-82. doi: 10.1002/mds.22307. Mov Disord. 2009. PMID: 19025777 Free PMC article. Clinical Trial.

4

Atomoxetine improves memory and other components of executive function in young-adult rats and aged rhesus monkeys.

Callahan PM, Plagenhoef MR, Blake DT, Terry AV Jr. Callahan PM, et al. Neuropharmacology. 2019 Sep 1;155:65-75. doi: 10.1016/j.neuropharm.2019.05.016. Epub 2019 May 18. Neuropharmacology. 2019. PMID: 31108108 Free PMC article.

5

Locus coeruleus integrity and the effect of atomoxetine on response inhibition in Parkinson's disease.

O'Callaghan C, Hezemans FH, Ye R, Rua C, Jones PS, Murley AG, Holland N, Regenthal R, Tsvetanov KA, Wolpe N, Barker RA, Williams-Gray CH, Robbins TW, Passamonti L, Rowe JB. O'Callaghan C, et al. Brain. 2021 Sep 4;144(8):2513-2526. doi: 10.1093/brain/awab142. Brain. 2021. PMID: 33783470 Free PMC article.

6

Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder.

Walker DJ, Mason O, Clemow DB, Day KA. Walker DJ, et al. Postgrad Med. 2015;127(7):686-701. doi: 10.1080/00325481.2015.1081046. Postgrad Med. 2015. PMID: 26343377 Review.

7

Improving response inhibition in Parkinson's disease with atomoxetine.

Ye Z, Altena E, Nombela C, Housden CR, Maxwell H, Rittman T, Huddleston C, Rae CL, Regenthal R, Sahakian BJ, Barker RA, Robbins TW, Rowe JB. Ye Z, et al. Biol Psychiatry. 2015 Apr 15;77(8):740-8. doi: 10.1016/j.biopsych.2014.01.024. Epub 2014 Feb 7. Biol Psychiatry. 2015. PMID: 24655598 Free PMC article. Clinical Trial.

8

Bradshaw SE, Agster KL, Waterhouse BD, McGaughy JA. Bradshaw SE, et al. Brain Res. 2016 Jun 15;1641(Pt B):245-57. doi: 10.1016/j.brainres.2016.01.001. Epub 2016 Jan 14. Brain Res. 2016. PMID: 26774596 Free PMC article.

9

Improvement of executive functions in boys with attention deficit hyperactivity disorder: an open-label follow-up study with once-daily atomoxetine.

Gau SS, Shang CY. Gau SS, et al. Int J Neuropsychopharmacol. 2010 Mar;13(2):243-56. doi: 10.1017/S1461145709990836. Epub 2009 Oct 23. Int J Neuropsychopharmacol. 2010. PMID: 19849892 Free article. Clinical Trial.

10

Targeting impulsivity in Parkinson's disease using atomoxetine.

Kehagia AA, Housden CR, Regenthal R, Barker RA, Müller U, Rowe J, Sahakian BJ, Robbins TW. Kehagia AA, et al. Brain. 2014 Jul;137(Pt 7):1986-97. doi: 10.1093/brain/awu117. Epub 2014 Jun 3. Brain. 2014. PMID: 24893708 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

81 results

Results by year